Shares of Niagen Bioscience (NASDAQ: NAGE) surged 20.53% in pre-market trading on Thursday, following the release of the company's impressive second-quarter financial results that significantly exceeded analyst expectations. The biotechnology firm not only reported strong earnings and revenue growth but also raised its full-year outlook, sparking investor enthusiasm.

Niagen Bioscience reported quarterly earnings of $0.04 per share, doubling the analyst consensus estimate of $0.02. The company's Q2 sales reached $31.117 million, surpassing the projected $28.324 million by 9.86%. Notably, this represents a robust 36.84% increase compared to the $22.739 million in sales reported for the same period last year. The strong performance was further underscored by a gross profit of $20.226 million and an operating income of $3.185 million for the quarter.

Adding to the positive sentiment, Niagen Bioscience raised its 2025 revenue outlook, now projecting 22%-27% year-over-year growth. This optimistic forward guidance, coupled with the company's ability to outperform in a challenging economic environment, has contributed to the significant stock rally. The bullish outlook is further supported by analysts, with H.C. Wainwright reiterating a "Buy" rating on NAGE stock. Wall Street's median 12-month price target for Niagen Bioscience stands at $16.00, representing a potential upside of approximately 42.8% from its last closing price.